Literature DB >> 9748022

Increased release of interleukin-12p40 in MS: association with intracerebral inflammation.

K Fassbender1, A Ragoschke, S Rossol, A Schwartz, O Mielke, A Paulig, M Hennerici.   

Abstract

OBJECTIVE: The p40 subunit of interleukin (IL)-12 was recently demonstrated in active lesions in MS. We tested whether the p40 subunit of IL-12 can also be detected in CSF and serum of patients with this disease and, if so, whether release is associated with inflammatory disease activity.
RESULTS: This study demonstrates an increased (up to 1,000-fold) compartmentalized release of the p40 subunit but not of the heterodimer p70 in MS. Release of IL-12p40 correlated with classic markers of CNS inflammation (CSF cell counts, immunoglobulin G index) and was significantly increased in patients with gadolinium-enhancing plaques on MRI. Moreover, release of IL-12p40 was associated with CSF levels of myelin basic protein as a measure of myelin degradation.
CONCLUSION: These results suggest a role of IL-12p40 in the pathophysiology of MS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748022     DOI: 10.1212/wnl.51.3.753

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  N-type calcium channel in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Naoki Tokuhara; Kana Namiki; Mai Uesugi; Chihiro Miyamoto; Makoto Ohgoh; Katsutoshi Ido; Takashi Yoshinaga; Toshihiko Yamauchi; Junro Kuromitsu; Sadao Kimura; Norimasa Miyamoto; Yoshitoshi Kasuya
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis.

Authors:  Makoto Matsui; Shin-ichi Araya; Hui-Yun Wang; Kouji Matsushima; Takahiko Saida
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

Review 3.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

4.  Role of cytokine p40 family in multiple sclerosis.

Authors:  S Brahmachari; K Pahan
Journal:  Minerva Med       Date:  2008-04       Impact factor: 4.806

Review 5.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

6.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

Review 7.  Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.

Authors:  Jacqueline M Benson; David Peritt; Bernard J Scallon; George A Heavner; David J Shealy; Jill M Giles-Komar; Mary Ann Mascelli
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

8.  Generation of functional blocking monoclonal antibodies against mouse interleukin-12 p40 homodimer and monomer.

Authors:  Subhajit Dasgupta; Mausumi Bandopadhyay; Kalipada Pahan
Journal:  Hybridoma (Larchmt)       Date:  2008-06

Review 9.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  Induction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages.

Authors:  Malabendu Jana; Subhajit Dasgupta; Ramendra N Saha; Xiaojuan Liu; Kalipada Pahan
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.